[Clinical study on the effect of vaginal administration of micronized progesterone at dysfunctional uterine bleeding in premenopause].

Abstract

The aim of the present study was to establish the effectiveness of vaginal administration of micronized progesterone at 37 premenopausal women aged between 40-49 years (mean 44.5) with dysfunctional uterine bleeding. All women were subject of classical dilatation and curettage and after that micronized progesterone (Utrogestan) was applied vaginally 3 tablets 2 times per day, starting at 14 day of the menstrual cycle for 12 days. The control examination has been performed after finishing of 6 months therapy. The main criteria for the assessment of the therapeutic effect was the comparison of the character of genital bleeding, vegetative symptoms before and after the administration of the gestagene, as well as the examination of the level of hemoglobin, the thickness of the endometrium and at 12 women the histological findings from the control curettage. The results of our study show the presence of statistically significant difference for the effectiveness of micronized progesterone at dysfunctional uterine bleeding according to the intensity (p = 0.0068), duration of the bleeding (p = 0.00), decreasing of the endometrial thickness (p = 0.00), as well as lack of such difference when follow the level of hemoglobin (p = 0.4663) and vegetative symptoms (p = 0.9555). On the basis of conducted clinical study the authors confirm the preventive effect of the micronized progesterone, as an effective and safe alternative in treating of premenopausal women with dysfunctional uterine bleeding.

• Authors: P Kostova, V Zlatkov
• Journal: Akusherstvo i ginekologiia (Akush Ginekol (Sofiia)) Vol. 48 Issue 2 Pg. 3-7 ( 2009) ISSN: 0324-0959 [Print] Bulgaria
• PMID: 20198768 (Publication Type: English Abstract, Journal Article)

Chemical References

• Progesterone

Topics

• Administration, Intravaginal
• Adult
• Female
• Humans
• Menstrual Cycle
• Middle Aged
• Premenopause
• Progesterone (administration & dosage, therapeutic use)
• Uterine Hemorrhage (drug therapy)